Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 18/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986604 | 0.93 | IGF1R (0.44) | IGF1RCDK9CCNT1MCHR1 | |
| SCHEMBL5538745 | 0.91 | SUV39H2 (0.38) | IGF1RCDK9CCNT1 | |
| SCHEMBL2987134 | 0.90 | CDK9 (0.39) | IGF1RCDK9CCNT1 | |
| SCHEMBL5535776 | 0.89 | IGF1R (0.41) | IGF1RCDK9CCNT1MCHR1 | |
| SCHEMBL2992501 | 0.89 | IGF1R (0.40) | IGF1RCDK9CCNT1 | |
| Hydrochloric Acid SCHEMBL2984613 | 0.89 | IGF1R (0.41) | IGF1RCDK9CCNT1MCHR1 | |
| SCHEMBL2995039 | 0.88 | IGF1R (0.42) | IGF1RCDK9CCNT1CASP3CASP7 | |
| SCHEMBL5533445 | 0.88 | IGF1R (0.42) | IGF1RCDK9CCNT1CASP3CASP7 | |
| Hydrochloric Acid SCHEMBL2989485 | 0.88 | IGF1R (0.41) | IGF1RCDK9CCNT1CASP3CASP7 | |
| SCHEMBL5532887 | 0.87 | IGF1R (0.43) | IGF1RCDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | IGF1R 606/4885CDK9 90/4885CCNT1 327/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | IGF1R 606/4885CDK9 90/4885CCNT1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.